GlassScriptPhysician profile
Jessica Long
NPI 1679245914
$3,988.19
in general payments reported to CMS, 2019-2025
17 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,153 · 2023: $1,459 · 2024: $753 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $764.26 | 2022-2025 | Biktarvy, Sunlenca, Veklury |
| Abbvie INC. | $649.41 | 2022-2024 | |
| Insmed, INC. | $456.12 | 2022-2025 | Arikayce |
| Viiv Healthcare Company | $405.81 | 2023-2025 | Dovato, Apretude, Cabenuva |
| Paratek Pharmaceuticals, INC. | $326.95 | 2022-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $323.01 | 2022-2025 | Xerava, Xacduro, Zevtera |
| Merck Sharp & Dohme LLC | $225.44 | 2022-2025 | Dificid, Pifeltro, Delstrigo |
| Theratechnologies INC. | $222.11 | 2022-2025 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $171.32 | 2022-2023 | Symtuza |
| Shionogi INC | $161.62 | 2022-2025 | Fetroja |
| Janssen Products, LP | $114.75 | 2023 | Symtuza |
| Melinta Therapeutics, LLC | $58.94 | 2023-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Tetraphase Pharmaceuticals, INC. | $32.73 | 2025 | |
| Global Blood Therapeutics, INC. | $24.70 | 2022 | |
| Cormedix INC. | $21.21 | 2025 | Defencath |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $14.99 | 2022 | |
| Mallinckrodt Hospital Products INC. | $14.82 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.